No Data
No Data
Immuneering Treatment of Pancreatic Cancer Granted FDA Orphan Status
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers
Can Immuneering (NASDAQ:IMRX) Afford To Invest In Growth?
Immuneering IMRX Phase 2a Data; NuCana NCNA Phase 2 Data
Outperform Rating Reaffirmed for Immuneering's Stock Amidst Promising IMM-1-104 Phase 2a Study Results
No Data
No Data
Matt101 : this will move again soon
Matt101 : would love if this could dip down so I can re-enter